⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180343 | 1.00 | — | — | |
| SCHEMBL3391091 | 1.00 | — | — | |
| SCHEMBL9244981 | 0.82 | — | — | |
| SCHEMBL24002525 | 0.79 | — | — | |
| SCHEMBL1785375 | 0.70 | — | — | |
| SCHEMBL823130 | 0.69 | — | — | |
| SCHEMBL823118 | 0.67 | — | — | |
| SCHEMBL10830667 | 0.67 | — | — | |
| SCHEMBL3540715 | 0.65 | — | — | |
| SCHEMBL2942948 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-20030125259-A1 | Octa- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-2177530-A1 | Octapeptide having antiangiogenic activity | Abbott Laboratories (US) | 2010-04-21 | — | — | EP | disclosed |
| US-7473696-B2 | CCR-2 antagonist salt | MERCK & CO., INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7361765-B2 | Process for the preparation of CCR-2 antagonists | MERCK & CO., INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | disclosed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | disclosed |
| US-20030125259-A1 | Octa- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | disclosed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | disclosed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | disclosed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | disclosed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | disclosed |